IR/PR

NovMetaPharma Co., Ltd. applied for a patent related to COVID-19 treatment in the United States on November 17th at the local time.  It will enter other regions outside the U.S. following PCT application. The substance that applied for a patent as a COVID-19 treatment is the core of NovMetaPharma Co., Ltd. It is in a high development stage that can enter the US FDA clinical trial phase 3 in terms of drug safety and production quality, so it is expected to be able to enter phase 2 based on the results of further research. We have confirmed the effect of the COVID-19 treatment through several research institutes, and the substance that applied for patent has strong anti-inflammatory and fibrosis inhibitory effects in the lungs and kidneys of cellular and animal fibrosis models. Thus, we expect to have treatment efficacy in lung and kidney-related complications as a COVID-19 vaccine.